Promotions & Moves

Alchemab Appoints New CEO

Jane Osbourn brings more than 30 years of biopharmaceutical industry experience to the CEO role.

Author Image

By: Charlie Sternberg

Associate Editor

Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as the company’s Chief Executive Officer (CEO) and a member of the Board.   As Co-Founder and CSO, Osbourn has led all aspects of Alchemab’s platform development and drug discovery activities to date and brings to the CEO role more than 30 years of biopharmaceutical industry experience.   Prior to co-founding Alchemab in 2019, Osbourn served as Vice President of R&D at Me...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters